New MRI scan could spot bone lesions without radiation
NCT ID NCT06988020
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an improved whole-body MRI that uses special 'pseudo-CT' sequences to detect bone lesions in people with multiple myeloma. The goal is to see if this single, radiation-free scan can accurately find bone damage. About 45 patients with newly diagnosed or recurrent myeloma will be scanned, and the results will be compared to standard imaging methods.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- MRI with ZTE sequences
- What this could lead to
- If successful, this MRI technique could become a more accurate, radiation-free way to detect bone lesions in multiple myeloma patients.
- What could go wrong
- This is a small, early-phase diagnostic study (45 participants) focused on accuracy, not treatment. The new sequences may not prove significantly better than current methods.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 45 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2025
- Expected to finish
-
Nov 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Patient with newly diagnosed multiple myeloma, for whom bone imaging is required for staging. * Recurrent patient after intensive treatment (high dose chemotherapy, bone marrow transplant, etc.). * Patient requiring a PET / CT considered as the technique of choice in these stages of the disease. Exclusion Criteria: * Implanted material incompatible with MRI. * Severe claustrophobia. * Pregnant women
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Multiple myeloma bone disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Cliniques universitaires Saint-Luc
RECRUITINGBrussels, Belgium